相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Efficacy and safety of low-dose IL-2 in the treatment of systemic lupus erythematosus: a randomised, double-blind, placebo-controlled trial
Jing He et al.
ANNALS OF THE RHEUMATIC DISEASES (2020)
An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 Diabetes
Kevan C. Herold et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Immunological and clinical effects of low-dose interleukin-2 across 11 autoimmune diseases in a single, open clinical trial
Michelle Rosenzwajg et al.
ANNALS OF THE RHEUMATIC DISEASES (2019)
T Regulatory Cells From Non-obese Diabetic Mice Show Low Responsiveness to IL-2 Stimulation and Exhibit Differential Expression of Anergy-Related and Ubiquitination Factors
Gloria J. Godoy et al.
FRONTIERS IN IMMUNOLOGY (2019)
De novo design of potent and selective mimics of IL-2 and IL-15
Daniel-Adriano Silva et al.
NATURE (2019)
Low-dose interleukin-2 therapy in refractory systemic lupus erythematosus: an investigator-initiated, single-centre phase 1 and 2a clinical trial
Jens Y. Humrich et al.
LANCET RHEUMATOLOGY (2019)
Dose-escalated interleukin-2 therapy for refractory chronic graft-versus-host disease in adults and children
Jennifer S. Whangbo et al.
BLOOD ADVANCES (2019)
IL-2 and Beyond in Cancer Immunotherapy
John M. Wrangle et al.
JOURNAL OF INTERFERON AND CYTOKINE RESEARCH (2018)
A long-lived IL-2 mutein that selectively activates and expands regulatory T cells as a therapy for autoimmune disease
Laurence B. Peterson et al.
JOURNAL OF AUTOIMMUNITY (2018)
Revisiting IL-2: Biology and therapeutic prospects
Abul K. Abbas et al.
SCIENCE IMMUNOLOGY (2018)
The DILfrequency study is an adaptive trial to identify optimal IL-2 dosing in patients with type 1 diabetes
Eleonora Seelig et al.
JCI INSIGHT (2018)
Targeting IL-2: an unexpected effect in treating immunological diseases
Congxiu Ye et al.
SIGNAL TRANSDUCTION AND TARGETED THERAPY (2018)
Engineering an IgG Scaffold Lacking Effector Function with Optimized Developability
Frederick W. Jacobsen et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2017)
Low-dose interleukin-2 selectively corrects regulatory T cell defects in patients with systemic lupus erythematosus
Caroline von Spee-Mayer et al.
ANNALS OF THE RHEUMATIC DISEASES (2016)
Reduced interleukin-2 responsiveness impairs the ability of Treg cells to compete for IL-2 in nonobese diabetic mice
Cini R. James et al.
IMMUNOLOGY AND CELL BIOLOGY (2016)
The importance of the Non Obese Diabetic (NOD) mouse model in autoimmune diabetes
James A. Pearson et al.
JOURNAL OF AUTOIMMUNITY (2016)
Low-dose interleukin-2 treatment selectively modulates CD4+ T cell subsets in patients with systemic lupus erythematosus
Jing He et al.
NATURE MEDICINE (2016)
Time-Dependent Regulation of IL-2R α-Chain (CD25) Expression by TCR Signal Strength and IL-2-Induced STAT5 Signaling in Activated Human Blood T Lymphocytes
Alla N. Shatrova et al.
PLOS ONE (2016)
Articular chondrocyte network mediated by gap junctions: role in metabolic cartilage homeostasis (vol 74, pg 275, 2015)
Maria D. Mayan et al.
ANNALS OF THE RHEUMATIC DISEASES (2015)
Sustained in vivo signaling by long-lived IL-2 induces prolonged increases of regulatory T cells
Charles J. M. Bell et al.
JOURNAL OF AUTOIMMUNITY (2015)
The promise of low-dose interleukin-2 therapy for autoimmune and inflammatory diseases
David Klatzmann et al.
NATURE REVIEWS IMMUNOLOGY (2015)
Control of the Inheritance of Regulatory T Cell Identity by a cis Element in the Foxp3 Locus
Yongqiang Feng et al.
CELL (2014)
Ultra Low-Dose IL-2 for GVHD Prophylaxis after Allogeneic Hematopoietic Stem Cell Transplantation Mediates Expansion of Regulatory T Cells without Diminishing Antiviral and Antileukemic Activity
Alana A. Kennedy-Nasser et al.
CLINICAL CANCER RESEARCH (2014)
The IL-2 cytokine family in cancer immunotherapy
Geok Choo Sim et al.
CYTOKINE & GROWTH FACTOR REVIEWS (2014)
Effects of Low-Dose Recombinant Interleukin 2 to Promote T-Regulatory Cells in Alopecia Areata
Emeline Castela et al.
JAMA DERMATOLOGY (2014)
Regulatory T cells control NK cells in an insulitic lesion by depriving them of IL-2
Jonathan Sitrin et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2013)
T-cell activation by treatment of cancer patients with EMD 521873 (Selectikine), an IL-2/anti-DNA fusion protein
Julien Laurent et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2013)
Exploiting a natural conformational switch to engineer an interleukin-2 'superkine'
Aron M. Levin et al.
NATURE (2012)
The role of interleukin-2 during homeostasis and activation of the immune system
Onur Boyman et al.
NATURE REVIEWS IMMUNOLOGY (2012)
A Low-Toxicity IL-2-Based Immunocytokine Retains Antitumor Activity Despite Its High Degree of IL-2 Receptor Selectivity
Stephen D. Gillies et al.
CLINICAL CANCER RESEARCH (2011)
A role for interleukin-2 trans-presentation in dendritic cell-mediated T cell activation in humans, as revealed by daclizumab therapy
Simone C. Wuest et al.
NATURE MEDICINE (2011)
Regulatory T-Cell Responses to Low-Dose Interleukin-2 in HCV-Induced Vasculitis
David Saadoun et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Interleukin-2 and Regulatory T Cells in Graft-versus-Host Disease
John Koreth et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Defects in IL-2R Signaling Contribute to Diminished Maintenance of FOXP3 Expression in CD4+ CD25+ Regulatory T-Cells of Type 1 Diabetic Subjects
S. Alice Long et al.
DIABETES (2010)
Central role of defective interleukin-2 production in the triggering of islet autoimmune destruction
Qizhi Tang et al.
IMMUNITY (2008)
IL-2 Family of Cytokines in T Regulatory Cell Development and Homeostasis
Thomas R. Malek et al.
JOURNAL OF CLINICAL IMMUNOLOGY (2008)
Nonredundant roles for Stat5a/b in directly regulating Foxp3
Zhengju Yao et al.
BLOOD (2007)
Foxp3-dependent programme of regulatory T-cell differentiation
Marc A. Gavin et al.
NATURE (2007)
Both integrated and differential regulation of components of the IL-2/IL-2 receptor system
Hyoung Pyo Kim et al.
CYTOKINE & GROWTH FACTOR REVIEWS (2006)
Human regulatory T cells and their role in autoimmune disease
Clare Baecher-Allan et al.
IMMUNOLOGICAL REVIEWS (2006)
Crystal structure of the IL-2 signaling complex: Paradigm for a heterotrimeric cytokine receptor
DJ Stauber et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
Structure of the quaternary complex of interleukin-2 with its α, β, and γc receptors
XQ Wang et al.
SCIENCE (2005)
A function for interleukin 2 in Foxp3-expressing regulatory T cells
JD Fontenot et al.
NATURE IMMUNOLOGY (2005)
Generation of low-toxicity interleukin-2 fusion proteins devoid of vasopermeability activity
PS Hu et al.
BLOOD (2003)
CD4+CD25high regulatory cells in human peripheral blood
C Baecher-Allan et al.
JOURNAL OF IMMUNOLOGY (2001)
A T-cell-selective interleukin 2 mutein exhibits potent antitumor activity and is well tolerated in vivo
AB Shanafelt et al.
NATURE BIOTECHNOLOGY (2000)
分享论文
